Anne Floquet

ORCID: 0000-0002-1078-8554 · 3 papers in corpus
nonrandomized-trial 2024
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Nature communications ·doi:10.1038/s41467-024-45974-w

Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to …

other 2023
Surgical restaging of patients with early‑stage endometrial cancer with lymphovascular invasion does not significantly impact their survival outcomes
Oncology letters ·doi:10.3892/ol.2023.13708

Lymphovascular space invasion (LVSI) is considered to be a poor prognostic factor in endometrial cancer. However, management of patients with early-stage endometrial cancer with positive LVSI remains controversial. The main objective of the…

observational 2021
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study
Gynecologic Oncology ·doi:10.1016/j.ygyno.2021.10.001

OBJECTIVE: We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gy…